Literature DB >> 17563247

Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.

James K Sheffield1, Joseph Jankovic.   

Abstract

Botulinum toxins are an effective treatment modality for a growing number of neurologic conditions. Although there has been varied interest and success in their use, they have been studied for a variety of conditions associated with Parkinson's disease. Conditions reviewed in this paper include hand and jaw tremor, dystonia, blepharospasm and apraxia of eyelid opening, bruxism, camptocormia, freezing of gait, sialorrhea and constipation. We will make comments when applicable on our unique experience with botulinum toxin in these conditions. Other conditions associated with Parkinson's disease, which will not be reviewed here, but may benefit from botulinum toxin treatment include anterocollis (also known as dropped head syndrome), hyperhidrosis, seborrhea and overactive bladder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563247     DOI: 10.1586/14737175.7.6.637

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  14 in total

Review 1.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

2.  Rabbit syndrome associated with medullary compression by vertebral artery.

Authors:  Hyung-Eun Park; Ji-Eun Lee; Byung-Chul Son; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2016-02-12       Impact factor: 3.307

Review 3.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

4.  A motor learning-based intervention to ameliorate freezing of gait in subjects with Parkinson's disease.

Authors:  Meir Plotnik; Shirley Shema; Moran Dorfman; Eran Gazit; Marina Brozgol; Nir Giladi; Jeffrey M Hausdorff
Journal:  J Neurol       Date:  2014-04-23       Impact factor: 4.849

Review 5.  An update on the use of botulinum toxin therapy in Parkinson's disease.

Authors:  Reversa Mills; Laxman Bahroo; Fernando Pagan
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

6.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

7.  Modification of blood vessel diameter following perivascular application of botulinum toxin-A.

Authors:  Peter B Arnold; Chris A Campbell; George Rodeheaver; Wyndell Merritt; Raymond F Morgan; David B Drake
Journal:  Hand (N Y)       Date:  2009-02-05

Review 8.  The zinc-dependent protease activity of the botulinum neurotoxins.

Authors:  Frank J Lebeda; Regina Z Cer; Uma Mudunuri; Robert Stephens; Bal Ram Singh; Michael Adler
Journal:  Toxins (Basel)       Date:  2010-05-07       Impact factor: 4.546

9.  Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.

Authors:  Lyndsey E Collins-Praino; Nicholas E Paul; Kristen L Rychalsky; James R Hinman; James J Chrobak; Patrick B Senatus; John D Salamone
Journal:  Front Syst Neurosci       Date:  2011-07-04

Review 10.  Disorders of the oral cavity in Parkinson's disease and parkinsonian syndromes.

Authors:  Yair Zlotnik; Yacov Balash; Amos D Korczyn; Nir Giladi; Tanya Gurevich
Journal:  Parkinsons Dis       Date:  2015-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.